DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions

Information source: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Primidone (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Dr. Reddy's Laboratories Limited

Official(s) and/or principal investigator(s):
Mohanlal shiva prasad sayana, Principal Investigator, Affiliation: Bioserve Clinical Research Pvt. Ltd., Hyderabad, A.P.

Summary

The purpose of this study is to assess the bioavailability of Primidone 50 mg tablets of Dr. Reddy's comparing with that of Mysoline@ tablets of Yamanouchi Pharma Technologies Inc, in healthy, adult, human subjects under fasting conditions.

Clinical Details

Official title: An Open Label, Balanced. Randomized, Two-treatment, Two-period, Two-sequence, Single Dose,Crossover, Bioequivalence Study of Primidone 50 mg Tablets of Comparing With That of MysolineŽ 50 mg Tablets Under Fasting Conditions.

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bioequivalence based on Cmax and AUC parameters

Detailed description: An open label, balanced. randomized, two-treatment, two-period, two-sequence, single dose,crossover, bioequivalence study of Primidone 50 mg tablets of Dr. Reddy's Laboratories Limited, Generics, India comparing with that of Mysoline (containing Primidone 50 mg) tablets of Yamanouchi Pharma Technologies Inc, Norman, OK in healthy, adult, human subjects under fasting conditions with a washout period of 14 days.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: 1. Subjects who will provide written informed consent. 2. Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive)weighing at least 50 kg. 3. Having a Body Mass Index (BMI) between 18. 5 and 24. 9 (both inclusive), calculated as weight in Kg/height in m2 4. Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study. 5. Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance. 6. Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent. Exclusion Criteria: The subjects will be excluded based on the following criteria during screening and during the study 1. Subjects incapable of understanding the informed consent. 2. Subjects who have: 1. Systolic blood pressure less than 90 mm ofHg or more than 140 mm of Hg 2. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator. 3. Pulse rate below 50/min or above 100/min. 3. History of hypersensitivity or idiosyncratic reaction to study drug or any other related drugs. 4. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. 5. Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study. 6. Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and during sampling period. 7. Subjects who have taken over the counter or prescribed medications and enzyme modifying or any systemic medication for during the last 7 and 30 days respectively before dosing. 8. Subjects who have participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study. 9. Subjects with clinically significant abnormalities (such as Laboratory Findings, ECG, X-Ray,Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV, Hey, Syphilis,Hepatitis B etc.,). 10. Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study.

Locations and Contacts

Bioserve Clinical Research Pvt. Ltd,, HYD, Andhra Pradesh 500 037, India
Additional Information

Starting date: August 2006
Last updated: May 26, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017